<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875455</url>
  </required_header>
  <id_info>
    <org_study_id>PHY1705</org_study_id>
    <nct_id>NCT04875455</nct_id>
  </id_info>
  <brief_title>Premium Trifocal IOL Comparative Analysis</brief_title>
  <official_title>Development of a Database (Register) for Quality Assurance and Optimization of the Postoperative Results of Premium Intraocular Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beaver-Visitec International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beaver-Visitec International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Short and long-term analysis of the refraction correction and optical image quality of modern&#xD;
      premium intraocular lenses (IOLs) with the establishment of a database for quality assurance&#xD;
      and optimization the computation constants of the lens power.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the investigational lens, like conventional IOLs, is a posterior chamber lens which is&#xD;
      widely implanted following cataract extraction, phacoemulsification is adopted. To assess the&#xD;
      binocular vision, the investigational lens will be mono- or bilaterally implanted.&#xD;
&#xD;
      Clinically retro- and prospective, non-randomized, uncontrolled, open study at several&#xD;
      centers: University Eye Clinic Heidelberg (leading center), Practice Center Ahaus in the Eye&#xD;
      Clinic Ahaus, Breyer, Kaymak &amp; Klabe Eye Surgery in D체sseldorf, nordBLICK Eye Center Kiel.&#xD;
&#xD;
      Main objectives:&#xD;
&#xD;
        1. Functional results (refraction and visual acuity results) Secondary goals:&#xD;
&#xD;
        2. Deviation target vs. achieved postoperative refraction (for constant optimization of the&#xD;
           IOL calculation)&#xD;
&#xD;
        3. Subjective patient satisfaction&#xD;
&#xD;
        4. Visual quality (e.g. scattered light, contrast vision, spherical aberrations)&#xD;
&#xD;
        5. Stability of the results achieved postoperatively&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Study procedure guidelines&#xD;
Patients who were previously treated with a premium IOL (Panoptix, POD FGF, POD F) are continuously included:&#xD;
Retrospective:&#xD;
Routine data collected up to the first study visit (preoperative, intraoperative and postoperative) are evaluated retrospectively&#xD;
Prospective:&#xD;
2-4 months postoperatively: refraction and vision, slit lamp and fundus examination, intraocular</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocular Best corrected distance visual acuity (5 m)</measure>
    <time_frame>Postoperative Day 75-105 (3 months)</time_frame>
    <description>CDVA measured with ETDRS charts placed in 5m distance with best aided corrective glasses according to ISO 11979-7:2014.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cataract</condition>
  <condition>Lens Opacities</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Experimental: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PhysIOL POD F GF: 50 (bilateral implantation) PhysIOL POD F: 50 (bilateral implantation) Alcon PanOptix: 20 (bilateral implantation) In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation</intervention_name>
    <description>In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.</description>
    <arm_group_label>Experimental: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Availability, willingness and sufficient cognitive awareness to comply with&#xD;
             examination procedures&#xD;
&#xD;
          -  Bilateral implantation of one of the following IOL models&#xD;
&#xD;
          -  Alcon PanOptix (TFNT00)&#xD;
&#xD;
          -  PhysIOL FineVision (POD F)&#xD;
&#xD;
          -  PhysIOL FineVision (POD F GF)&#xD;
&#xD;
          -  Uneventful cataract surgery with first clinical outcomes in the expected range&#xD;
&#xD;
          -  Patient included in Premium IOL study protocol by signed informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Age of patient &lt;45 years&#xD;
&#xD;
          -  Irregular astigmatism&#xD;
&#xD;
          -  Postoperative manifested astigmatism of &gt;1.0 D&#xD;
&#xD;
          -  Difficulty for cooperation (distance from their home, general health condition)&#xD;
&#xD;
          -  Clinically significant glaucoma&#xD;
&#xD;
          -  Clinically significant macular degeneration, clinically significant macular edema or&#xD;
             proliferative diabetic retinopathy&#xD;
&#xD;
          -  Patients with keratoconus or keratectasia&#xD;
&#xD;
          -  Any ocular comorbidity having a significant effect on the postoperative clinical&#xD;
             outcomes&#xD;
&#xD;
          -  History of ocular trauma or prior ocular surgery including refractive procedures&#xD;
&#xD;
          -  Capsule or zonular abnormalities that may affect postoperative centration or tilt of&#xD;
             the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)&#xD;
&#xD;
          -  Pupil abnormalitis (non-reactive, tonic pupils, abnormally shaped pupils or pupils&#xD;
             that do not dilate under mesopic/scotopic conditions)&#xD;
&#xD;
          -  AMD&#xD;
&#xD;
          -  Intraoperative complications like capsular rupture etc.&#xD;
&#xD;
          -  Patients who do not give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Auffarth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca McQuaid, PhD</last_name>
    <phone>+353871212615</phone>
    <email>Rmcquaid@bvimedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Augenklinik Ahaus</name>
      <address>
        <city>Ahaus</city>
        <zip>48683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Mueller</last_name>
      <phone>+49 2561 9555 247</phone>
      <email>m.mueller@augenklinik.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Gerl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internationale Innovative Ophthalmochirgie</name>
      <address>
        <city>D체sseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M체cella Kirca</last_name>
      <phone>49-211-58675748</phone>
      <email>m.kirca@augenchirurgie.clinic</email>
    </contact>
    <contact_backup>
      <last_name>Manusha Sathiyabalan</last_name>
      <phone>49-211-58675748</phone>
      <email>m.sathiyabalan@augenchirurgie.clinic</email>
    </contact_backup>
    <investigator>
      <last_name>Detlev Breyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karsten Klabe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universit채ts-Augenklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Willrich Amroussi, MA</last_name>
      <phone>+49 6221 56-36849</phone>
      <email>Raquel.WillrichAmroussi@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Ramin Khoramnia, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerd U Auffarth, MD, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timur M Yildirim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annette Stengele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augentagesklinik Rheine</name>
      <address>
        <city>Rheine</city>
        <zip>48429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafaela Lucchesi</last_name>
      <phone>+49 5971 8070 960</phone>
      <email>r.lucchesi@augenklinik.de</email>
    </contact>
    <investigator>
      <last_name>Florian Kretz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 1, 2021</study_first_submitted>
  <study_first_submitted_qc>May 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular lens</keyword>
  <keyword>Trifocal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

